These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36514192)

  • 1. Pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizers.
    Chung WK; Hwang I; Kim B; Jung J; Yu KS; Jang IJ; Oh J
    Clin Transl Sci; 2023 Mar; 16(3):512-523. PubMed ID: 36514192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single Dose and Repeat Once-Daily Dose Safety, Tolerability and Pharmacokinetics of Valbenazine in Healthy Male Subjects.
    Luo R; Bozigian H; Jimenez R; Loewen G; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):44-52. PubMed ID: 28839339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
    Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study.
    Factor SA; Remington G; Comella CL; Correll CU; Burke J; Jimenez R; Liang GS; O'Brien CF
    J Clin Psychiatry; 2017; 78(9):1344-1350. PubMed ID: 29141124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites.
    Grigoriadis DE; Smith E; Hoare SRJ; Madan A; Bozigian H
    J Pharmacol Exp Ther; 2017 Jun; 361(3):454-461. PubMed ID: 28404690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials.
    Thai-Cuarto D; O'Brien CF; Jimenez R; Liang GS; Burke J
    Drug Saf; 2018 Apr; 41(4):429-440. PubMed ID: 29218680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2017 Jul; 71(7):. PubMed ID: 28497864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of valbenazine in Japanese patients with tardive dyskinesia: A multicenter, randomized, double-blind, placebo-controlled study (J-KINECT).
    Horiguchi J; Watanabe K; Kondo K; Iwatake A; Sakamoto H; Susuta Y; Masui H; Watanabe Y
    Psychiatry Clin Neurosci; 2022 Nov; 76(11):560-569. PubMed ID: 36114799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
    Citrome L
    Expert Rev Neurother; 2018 Apr; 18(4):323-332. PubMed ID: 29557243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A long-term, open-label study of valbenazine for tardive dyskinesia.
    Lindenmayer JP; Verghese C; Marder SR; Burke J; Jimenez R; Siegert S; Liang GS; O'Brien CF
    CNS Spectr; 2021 Aug; 26(4):345-353. PubMed ID: 32419679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
    Khorassani F; Luther K; Talreja O
    Am J Health Syst Pharm; 2020 Jan; 77(3):167-174. PubMed ID: 31974564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.
    McIntyre RS; Calabrese JR; Nierenberg AA; Farahmand K; Yonan C; Siegert S; Burke J
    J Affect Disord; 2019 Mar; 246():217-223. PubMed ID: 30583148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and Pharmacologic Characterization of the Dihydrotetrabenazine Isomers of Deutetrabenazine and Valbenazine.
    Brar S; Vijan A; Scott FL; Jimenez R; Zhang H; Grigoriadis DE; Loewen G
    Clin Pharmacol Drug Dev; 2023 Apr; 12(4):447-456. PubMed ID: 36530055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
    Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
    Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valbenazine for the treatment of tardive dyskinesia.
    Müller T
    Expert Rev Neurother; 2017 Dec; 17(12):1135-1144. PubMed ID: 28971695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
    Caroff SN; Aggarwal S; Yonan C
    J Comp Eff Res; 2018 Feb; 7(2):135-148. PubMed ID: 28965423
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.